What's in Regeneron's pipeline?

Regeneron has 13 drugs in our index: 12 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Regeneron's portfolio?

Top competitors by shared drug class: AMGEN INC, AstraZeneca, SAMSUNG BIOEPIS CO LTD.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/regeneron.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Regeneron — Portfolio Competitive Intelligence Brief

Regeneron (REGN) pipeline: 12 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

REGN (NASDAQ) 12 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Veopoz	POZELIMAB	marketed	Complement Inhibitor [EPC]	Complement C5	Immunology	2023-01-01
Evkeeza	EVINACUMAB	marketed	Angiopoietin-like 3 Inhibitor [EPC]	Angiopoietin-related protein 3	Metabolic	2021-01-01
Inmazeb	ODESIVIMAB	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A	Immunology	2020-01-01
Inmazeb	ATOLTIVIMAB	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A	Immunology	2020-01-01
Ronapreve	CASIRIVIMAB	marketed			Infectious Disease	2020-01-01
Inmazeb	MAFTIVIMAB	marketed			Infectious Disease	2020-01-01
Libtayo	CEMIPLIMAB	marketed		PD-1	Oncology	2018-01-01
Dupixent	DUPILUMAB	marketed	Interleukin-4 Receptor alpha Antagonist [EPC]	Interleukin-4 receptor subunit alpha	Immunology	2017-01-01
Vegf Trap	AFLIBERCEPT	marketed	Vascular Endothelial Growth Factor Inhibitor	Vascular endothelial growth factor A	Oncology	2011-01-01
Arcalyst	RILONACEPT	marketed		Interleukin-1 beta	Rare Disease	2008-01-01
EVKEEZA	EVINACUMAB-DGNB	marketed	Angiopoietin-like 3 Inhibitor [EPC]	Angiopoietin-related protein 3	Metabolic
VEOPOZ	POZELIMAB-BBFG	marketed	Complement Inhibitor [EPC]	C5	Other

Therapeutic area mix

Immunology · 4
Infectious Disease · 3
Metabolic · 2
Oncology · 2
Other · 1
Rare Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AMGEN INC · 1 shared drug class
AstraZeneca · 1 shared drug class
SAMSUNG BIOEPIS CO LTD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Regeneron:

Cite this brief

Drug Landscape (2026). Regeneron — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/regeneron. Accessed 2026-05-13.